Both Sanofi and Regeneron added about 6 billion to their market caps today. That means they were both up about three times Insmeds total market cap. I think we know from following Insmed that Bronchiectasis and COPD are different, with overlapping conditions. It’s one of those strange occurrences that may actually put some eyes on little known Insmed. Now I have to add REGN and SNY to the list of potential suitors. Dupixents most common problem is pain at the injection site. Swallowing a pill is painless. (For most)